Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Statement of Financial Activities
(including income and expenditure account)
Year ended 31 March 2024
2024
Restricted
funds Total funds Total funds
2023
Unrestricted
funds
Note
Income and endowments
Donations and legacies
Charitable activities
Investment income
Other income
465,122
465,122
448,732
19,716
50
368,034
291,283
18,880
4,073
448,732
19,716
50
Total income
468,498
465,122
933,620
682,270
Expenditure
Expenditure on charitable activities
Total expenditure
9,10
{358.154) (277,732) (635,886) (603,703)
{358,154) (277,732) (635,886) (603,703)
Net (losses)Igains on investments
11
16.210
16,210
(56,329)
Net incomel(expenditure)
126,554
187,390
313.944
22.238
Transfers between funds
Net movement in funds
126,554
187,390
313,944
22,238
Reconciliation of funds
Total funds brought forward
Total funds carried forward
923,992
923,992
901,754
1.050,546
187,390
1,237,936
923,992
The statement of financial acb'vities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing acts"vities.
The notes on pages 15 to 24 fomi part of these financial statements.
12

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Statement of Financial Position
31 March 2024
2024
2023
Fixed assets
Investments
15
714,620
714,620
698,411
698,411
Current assets
Debtors
Cash at bank and in hand
16
146,063
537,379
110,380
258,096
683,442
308,476
Creditors: amounts falling due within one year
Net current assets
17
(160,126) (142,895)
523,316
225,581
Total assets less current liabilities
1.237,936
1.237,936
923,992
923,992
Net assets
Funds of the charity
Restricted funds
Unrestricted funds
187,390
1.050.546
923.992
Total charity funds
18 1,237,936
923,992
These financial statements were approved by the board of trustees and authorised for issue on 10th
December 2024 and are signed on behalf of the board by:
Mr R Buchanan
Trustee
The notes on pages 15 to 24 fomi part of these financial ststements.
13

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Statement of Cash Flows
Year ended 31 March 2024
2024
2023
Cash flows from operating activities
Net incomel(expenditure)
313.944
22,238
Adjustments for."
Net (losses)Igains on investments
Dividends, interest and rents from investments
Other interest receivable and similar income
Gains on disposal of tangible fixed assets
(16,210)
(19.716)
56,329
(18,880)
Changes in."
Trade and other debtors
Trade and other creditors
(35.683)
17.231
(60,380)
(110,277)
(110,970)
Cash generated from operab'ons
259,566
Interest re￿iVed
Net cash used in operating acb'vities
259,566
(110,970)
Cash flows from investing activities
Dividends. interest and rents from investrnents
Proceeds from sale of intangible assets
Purchases of other investments
Proceeds from sale of other investments
19.716
18.880
790
(30,433)
42,636
49,818
Net cash from investing activities
31,918
69,488
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
291,484
272,451
(41,482)
313,933
563,936
272,451
The notes on pages 15 to 24 forni part of these financial statements.
14

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements
Year ended 31 March 2024
General infomiation
The charity is a public benefit entity and a private company limited by guarantee, registered in
England and Wales and a registered charity in Northern Ireland. The address of the registered
office is Patrick G Johnston Centre for Cancer Research, 97 Lisburn Road, Belfast, BT9 7AE.
statement of compliance
These financial statements have been pEpared in compliance with FRS 102, 'The Financial
Reporting Standard applicable in the UK and the Republic of Ireland,, the Statement of
Recommended Practice applicable to charities preparing their accounts in accordance with the
Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities
SORP (FRS 102)) and the Companies Act 2006.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the
revaluation of certain financial assets and liabilities and investment properties measured at fair
value through income or expenditure.
The financial statements are prepared in sterling. which is the functional currency of the entity.
Going concern
There are no material Un￿rtaIntieS about the charity's ability to continue.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make Judgements,
estimates and assumptions that affect the amounts reported. These estimates and judgements
are continually reviewed and are based on experience and other factors, including expectations
of future events that are believed to be reasonable under the circumstances.
Fund accounting
Unrestricted funds are available for use at the discretion of the trustees to further any of the
charity's purposes.
Designated funds are unrestricted funds earmarked by the trustees for particular future project or
commitment.
Restricted funds are subjected to restrictions on their expenditure declared by the donor or
through the terms of an appeal. and fall into one of two sub-classes.. restricted income funds or
endowment funds.
15

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements fcontlnued)
Year ended 31 March 2024
Accounting policies (continued)
Incoming resources
All incoming resources are included in the statement of financial activities when entitlement has
passed to the charity; it is probable that the economic benefits associated with the transaction
will flow to the charity and the amount can be reliably measured. The following specific policies
are applied to particular categories of income-.
income from donations or grants is recognised when there is eviden￿ of entrtlement to the
gift, receipt is probable and its amount cAn bp. mpasiired reliably.
legacy income is recognised when receipt is probable and entitlement is established.
income from donated goods is measured at the fair value of the goods unless this is
impractical to measure reliably, in which case the value is derived from the cost to the donor
or the estimated resale value. Donated facilitias and services are racognised in the
accounts when received if the value can be reliably measured. No amounts are included for
the contribution of general volunteers.
income from contracts for the supply of sendices is recognised with the delivery of the
contracted service. This is classtfied as unrestricted funds unless there is a contractual
requirement for it to bc spcnt on a particular purpose and ￿turned if unspent, in whiGh case
it may be regarded as restricted.
Resources expended
Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any
VAT which cannot be fully recovered, and is classified under headings of the statement of
financial activities to which it relates:
expenditure on raising funds includes the costs of all fundraising activities, events.
non-charitable trading activities, and the sale of donated goods.
expenditure on charitable activities includes all costs inGurred by a charity in undertaking
activities that further its charitable aims for the benefit of its beneficiaries, including those
support costs and costs relating to the governance of the charity apportioned to charitable
activities.
other expenditure includes all expenditure that is neither related to raising funds for the
charity nor part of its expenditure on charitable activities.
All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs
attributable to a single activity are allocated directly to that activity. Shared costs are apportioned
between the activities they contribute to on a reasonable, justifiable and consistent basis.
16

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements fconlinued)
Year ended 31 March 2024
Accounting policies (conlinued)
Intangible assets
Intangible assets are initially recorded at cost. and are subsequently stated at cost less any
accumulated amortisation and impaimient losses. Any intangible assets carried at revalued
amounts, are recorded at the fair value at the date of revaluation, as determined by reference to
an active market, less any subsequent accumulated amortisation and subsequent accumulated
impairment losses.
Intangible assets acquired as part of a business combination are only recognised separately from
goodwill when they arise from contractual or other legal rights, are separable, the expected future
economic benefits are probable and the cost or value can be measured reliably.
Investments
Investments
2024
2023
Cash
Bonds
Alternatives & Multi-Asset
Equities
TOTAL - Managed Portfolio
26,577
47,008
136,521
504,514
714,620
14,360
66,949
133,425
483,677
698,411
Investments in associates
Investrnents in associates accounted for in accordance with the cost model are recorded at cost
less any accumulated impainnent losses.
Investments in associates accounted for in accordance with the fair value model are initially
recorded at the transaction price. At each reporting date, the investments are measured at fair
value, with changes in fair value taken through income or expenditure. V￿ere it is impracticable
to measure fair value reliably without undue cost or effort. the cost model will be adopted.
Dividends and other distributions received from the investment are recognised as income without
regard to whether the distributions are from accumulated profits of the associate arising before or
after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordan￿ wtth the cost model are
recorded at cost less any accumulated impairment losses.
Investments in jointly controlled entities accounted for in accordance with the fair value model are
initially recorded at the transaction price. At each reporting date, the investments are measured
at fair value, with changes in fair value tsken through income or expenditure. ￿ere it is
impracticable to measure fair value reliably without undue cost or effort, the cost model will be
adopted.
17

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements (condnued)
Year ended 31 March 2024
Accounting policies (continued)
Investments in joint ventures fcontinuedj
Dividends and other distributions received from the investment are recognised as income without
regard to whether the distributions are from accumulated profits of the joint venture arising before
or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impaiment is carried out at each reporting date, with the recoverable
amount being estimated where such indicators exist. Vvhere the carrying value exceeds the
recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for
possible reversal at each reporting date.
For the purposes of impaimient testing. when it is not possible to estimate the recoverable
amount of an individual asset. an estim2tp 1£ mAdp nf thp rernverAble amoLAnt of the
cash-generating unit to which the asset belongs. The cash-generating unit is the smallest
identifiable group of assets that includes the asset and generates cash inflows that largely
independent of the cash inflows from other assets or groups of assets.
For impairment testing of goodwill, the goodwill acquired in a business combination is, from the
acquisition date, allocated to @ach of the cash-generating units that are expected to benefit from
the synergies of the combination, irrespective of whether other assets or liabilities of the charity
are assigned to those units.
Financial instruments
A financial asset or a financial liability is recognised only when the charity becomes a party to the
contractual provisions of the instrument.
Basic financial instruments are initialty recognised at the amount receivable or payable including
any related transaction costs.
Current assets and current liabilities are subsequently measured at the cash or other
considerab'on expected to be paid or received and not discounted.
Debt instruments are subsequently rneasured at amortised cost.
Ihere investments in shares are publicly traded or their fair value can otherwise be measured
reliably, the investment is subsequently measured at fair value with changes in fair value
recognised in income and expenditure. All other such investmersts are subsequently measured at
cost less impairment
Other financial instruments. including derivatives, are inits-ally recognised at fair value, unless
payment for an asset is deferred beyond nonnal business terms or financed at a rate of interest
that is not a market rate, in which case the asset is measured at the present value of the future
payments discounted at a market rats of interest for a similar debt instrument.
Other financial instruments are subsequently measured at fair value, with any changes
recognised in the statement of financial activities. with the ex￿ptIOn of hedging instruments in a
designated hedging relationship.
18

Leukaemia and Lymphoma Nl
Company Limited by Guarantse
Notes to the Financial Statements (ci¥ntinuedJ
Year ended 31 March 2024
Accounting policies fcontsnued)
Financial instruments (continued)
Financial assets that are measured at cost or amortised cost are reviewed for objects've evidence
of impairment at the end of each reporting date. If there is objective evidence of impairment, an
impairment loss is recognised under the appropriate heading in the statement of financial
activities in which the inits'al gain was recognised
For all equity instruments regardless of significance. and other financial assets that are
individually significant. these are assessed individually for imp2irment. Othpr fin2nr.ial assets are
either assessed individually or grouped on the basis of similar credit risk Gharacteristics.
Any reversals of impairment are recognised immediately. to the extent that the reversal does not
result in a carrying amount of the financial asset that exceeds what the carrying amount would
have been had the impairment not previously been recognised.
Limited by guarantee
The company. being a company limited by guarantee. does not have share capital. The liability of
members of the company is limited to £1 per member.
Donations and legacies
Unrestricted
Funds
Restricted Total Funds
Funds
2024
Grants
Grant Income
465,122
465,122
Unrestricted
Funds
Restricted Total Funds
Funds
2023
Grants
Grant Income
368,034
368,034
Charitable activities
Unrestricted Total Funds Unrestricted Total Funds
Funds
2024
Funds
2023
Donations
Legacies
Trading Activities
Branch Income
Stem cell harvest
352,745
55,154
15.413
25.420
352,745
55.154
15,413
25,420
235,702
16,000
11,751
23,870
3,960
235,702
16,000
11,751
23,870
3,960
448.732
448,732
291,283
291,283
19

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements (contlnuedj
Year ended 31 March 2024
Investment income
Unrestricted Total Funds Unrestricted Total Funds
Funds
2024
Funds
2023
Investment Income
19,716
19.716
19.716
18,880
18,880
19,716
18,880
18,880
Other income
Unrestricted Total Funds Unrestricted Total Funds
Funds
2024
Funds
2023
Sundry Income
50
50
4,073
4,073
Expenditure on charitable activities by fund type
Unrestricted
Funds
Restricted Total Funds
Funds
2024
Charitable Activities
358.429
277.733
636.162
Unrestricted
Funds
Restricted Total Funds
Funds
2023
Charitable Activities
243,169
360,534
603,703
10. Expenditure on charitable activities by activty type
Activities
undertaken Total funds
directly
2024
Total fund
2023
Charitable Activities
636,162
636,162
603,703
11. Net (losses)Igains on investments
Unrestricted Total Funds Unrestricted Total Funds
Funds
2024
Funds
2023
Movement on valuation of investments
16.210
16,210
(56,329)
(56,329)
12. Auditors remuneration
2024
2023
Fees payable for the audit of the financial statements
4,975
4,740
20

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements (continued)
Year ended 31 March 2024
13. Staff costs
The total staff costs and employee benefits ft)r the reporting period are analysed as follows..
2024
2023
Wages and salaries
82,221
109,207
LLNI do not employ staff directly. staff are employed by a third paty, Queens University, and
LLNI pays grants towards the salaries of those employees working for LLNI, therefore a
breakdown of the costs between salaries, pension etc is not possible.
The average head count of employees during the year was Nil (2023: Nil).
No employee received employee benefits of more than £60,000 during the year (2023.. Nil).
14. Trustee remuneration and expenses
Trustees did not re￿1ve ￿MUneratIon or reimbursement of expenses during the year. (2023:
£Nil}
15. Investments
Cash or cash
Listed
equivalents investments
Total
Cost or valuation
At 1 April 2023
Additions
Disposals
Fair value movements
Other movements
14,355
684,056
22,920
{10,672)
4,006
(12,247)
688,063
698,411
22,920
(10,672)
4,006
(45)
714,620
12,202
26,557
At 31 March 2024
Impairnient
At 1 April 2023 and 31 March 2024
Carrying amount
At 31 March 2024
26,557
688,062
714,620
698,411
At 31 March 2023
14.355
684,056
All investments shown above are held at valuation.
Financial assets held at fair value
The listed investments are valued by Evelyn Partners, Belfast and held at market value.
16. Debtors
2024
2023
Other debtors
146,063
110,380
21

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements (continued)
Year ended 31 March 2024
17. Creditors: amounts falling due within one year
2024
2023
Accruals and deferred income
160,126
142,895
18. Analysis of charitable funds
Unrestricted funds
At
1 Apr 2023
Galns ano
At
losses 31 Mar 2024
Income Expenditure
Transfers
General funds
Clinic trials nurse
PhD Studentship
Research Grants
137,082
80,230
292,314
414,366
468,498
(130.050) (360,753)
(21.555)
(2,491)
(204,333)
358.429
16.485
131,262
58,675
359,246
501,363
69,423
291,330
923,992
468.498
16,485 1.050,546
At
1 Apr 2022
Gains and
At
losses 31 Mar 2023
Income ExpendÈture
Transfers
General funds
Clinic trials nurse
PhD Studentship
Research Grants
147,998
24,062
296,065
409,934
314,236
(146,808) {122,015) (56,329)
(13,832)
70,000
{3,751)
86.961
137,082
80,230
292,314
414,366
(82,529)
314,236 (243.169)
878,059
31.195
(56,329)
923,992
The designated funds have been set aside by LLNI as result of awards of various grants
approved by the Board of LLNI for future research projects.
Rostricted funds
At
1 Apr 2023
Gains and
At
losses 31 Mar 2024
Income Expenditure
Transfers
PhD Studentship
Research Grant
126,815
338,307
(126.815)
(150.917)
(277,732)
187,390
187,390
465.122
At
1 Apr 2022
Gains and
At
losses 31 Mar 2023
Income Expenditure
Transfers
PhD Studentship
Research Grant
26,695
111.752
256,282
(111,752) (23,695)
(248,782)
(7,500)
(360,534) (31,195)
23.695
368,034
22

Leukaemia and Lymphoma Nl
Company Limited by Guarantee
Notes to the Financial Statements (continuedj
Year ended 31 March 2024
18. Analysis of charitable funds (contlnuedj
The restricted funds were received from the Medical Research Council for the UK Government
and a donation of £200,000 for the MyBlock Project. The aim of the funding was to support early
areer researchers undertaking medical research and to protect the pipeline of early career
researchers and future research leaders. The transfer out of restricted funds relates to a
correction of the opening balance.
19. Analysis of net assets between funds
Unrestricted
Funds
Restricted ToLIl Funds
Funds
2024
Intangible assets
Investments
Current assets
Creditors less than 1 year
Net assets
714,620
445,658
{109.732)
1,050,546
714,620
683,442
(160,126)
1,237,936
237,784
(50,394}
187.390
Unrestricted
Funds
Restricted Total Funds
Funds
2023
Intangible assets
Investments
Current assets
Credrtors less than 1 year
Not assets
698,411
295,061
(69,480)
923,992
698,411
368,476
(142,895)
923,992
73,415
{73,415)
20. Taxation
The Company is a registered charity. and as such is entitled to tax exemptions on income and
profits in furtherance of the charity's primary objecb'ves.
21. Contingent liability
A contingent liability exists to repay grants received should certain conditions not be fulfilled by
the charity. In the opinion of the Trustees, the terms of the Letters of Offers have been, or will be,
complied with and no liability is expected.
22. Anatysis of changes in net debt
At
At 1 Apr 2023 Cash flows 31 Mar 2024
Cash at bank and in hand
258,096
279,283
537,379
24